Biopharmaceutical firm Parexel, which employs 18,660 staff, has been recognised for the support it provides to staff and their families in detecting cancer and supporting those coping with the disease.
Parexel has been accredited as a CEO Gold Standard employer by the US-based CEO Roundtable on Cancer, a non-profit organisation that has developed and administers an employee wellness framework to address cancer in the workplace.
To earn US-accreditation, employers must evaluate their corporate culture and the health benefits available to US employees, and take extensive action around cancer risk prevention, screening and support.
Parexel offers programmes aimed at reducing cancer risk, such as support for staff to quit smoking, and promoting physical activity, healthy eating and weight management.
It also offers a medical incentive programme to reduce an employee’s health plan contribution following the completion of health and wellness activities.
Its other measures to address cancer in the workplace include health insurance options to detect cancer at its earliest stages, access to care and participation in cancer clinical trials.
Josef von Rickenbach (pictured), chairman and chief executive office at Parexel, said: “We have a passion for making a profound difference in the lives of people, especially our employees and their families. We are honoured the CEO Roundtable on Cancer named us a Gold Standard employer, recognising our commitment to the health and wellbeing of our most important asset: our employees.”
